The Fate of Intranasally Instilled Silver Nanoarchitectures
Source abstract
Abstract
The intranasal administration of drugs allows an effective and noninvasive therapeutic action on the respiratory tract. In an era of rapidly increasing antimicrobial resistance, new approaches to the treatment of communicable diseases, especially lung infections, are urgently needed. Metal nanoparticles are recognized as a potential last-line defense, but limited data on the biosafety and nano/biointeractions preclude their use. Here, we quantitatively and qualitatively assess the fate and the potential risks associated with the exposure to a silver nanomaterial model (i.e., silver ultrasmall-in-nano architectures, AgNAs) after a single dose instillation. Our results highlight that the biodistribution profile and the nano/biointeractions are critically influenced by both the design of the nanomaterial and the chemical nature of the metal. Overall, our data suggest that the instillation of rationally engineered nanomaterials might be exploited to develop future treatments for (non)communicable diseases of the respiratory tract.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Inhalation and Respiratory Drug Delivery · Nanoparticles: synthesis and applications · Advanced Nanomaterials in Catalysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Center for Nanotechnology Innovation@ NEST, Istituto Italiano di Tecnologia, Piazza San Silvestro, 12−56127, Pisa, Italy
NEST-Scuola Normale Superiore, Piazza San Silvestro, 12−56127, Pisa, Italy
Translational Pharmacology, Istituto Italiano di Tecnologia, Via Morego, 30−16163, Genoa, Italy
Electron Microscopy Facility, Istituto Italiano di Tecnologia, Via Morego, 30−16163, Genoa, Italy
Funding
Associazione Italiana per la Ricerca sul Cancro · Ministero della Salute
References (64)
Show source-provided references
1. SCCS (Scientific Committee on Consumer Safety) Scientific advice on the safety of nanomaterials in cosmetics, preliminary version of 6 October 2020, final version of 8 January 2021, SCCS/1618/20, Corrigendum of 8 March 2021.
2. Epstein M. · Final Opin. · 2015 · 1
3. 10.1016/j.impact.2021.10031010.1016/j.impact.2021.100310 ↗
4. 10.1002/adhm.20170150310.1002/adhm.201701503 ↗
5. 10.1016/S0140-6736(01)23965-810.1016/S0140-6736(01)23965-8 ↗
6. 10.3390/pharmaceutics1202014210.3390/pharmaceutics12020142 ↗
7. 10.1002/wnan.170710.1002/wnan.1707 ↗
8. 10.1002/adma.20170430710.1002/adma.201704307 ↗
9. 10.2147/TCRM.S145810.2147/TCRM.S1458 ↗
10. 10.1016/j.impact.2016.06.00110.1016/j.impact.2016.06.001 ↗
11. 10.3390/ijms2107237510.3390/ijms21072375 ↗
12. 10.3109/17435390.2016.114879310.3109/17435390.2016.1148793 ↗
13. 10.1093/toxsci/kfn24610.1093/toxsci/kfn246 ↗
14. 10.1080/0895837070187467110.1080/08958370701874671 ↗
15. 10.1016/j.yrtph.2020.10469010.1016/j.yrtph.2020.104690 ↗
16. 10.1039/C2EM30595J10.1039/C2EM30595J ↗
17. 10.3390/ma606229510.3390/ma6062295 ↗
18. Bonner J. C. · Interaction of Nanomaterials with the Immune System · 202010.1007/978-3-030-33962-3 ↗
19. 10.1002/jat.326010.1002/jat.3260 ↗
20. 10.1021/acsnano.7b0187310.1021/acsnano.7b01873 ↗
21. 10.1186/1743-8977-10-3610.1186/1743-8977-10-36 ↗
22. 10.1021/nn302649p10.1021/nn302649p ↗
23. SCENIHR (Scientific Committee on Emerging and Newly Identified Health Risks) · 2014
24. 10.1186/1743-8977-10-1110.1186/1743-8977-10-11 ↗
25. 10.3390/biomedicines909121510.3390/biomedicines9091215 ↗
26. 10.1016/j.isci.2022.10398010.1016/j.isci.2022.103980 ↗
27. 10.1021/acsabm.9b0063010.1021/acsabm.9b00630 ↗
28. 10.1039/D0NA00521E10.1039/D0NA00521E ↗
29. 10.1002/ppsc.20180046410.1002/ppsc.201800464 ↗
30. 10.1021/acsanm.8b0024710.1021/acsanm.8b00247 ↗
31. 10.1016/j.nano.2018.05.00710.1016/j.nano.2018.05.007 ↗
32. 10.1021/acsomega.8b0171910.1021/acsomega.8b01719 ↗
33. 10.3390/cancers1205106310.3390/cancers12051063 ↗
34. 10.1021/acs.jpcc.6b1179910.1021/acs.jpcc.6b11799 ↗
35. 10.1016/j.jcis.2020.08.05910.1016/j.jcis.2020.08.059 ↗
36. 10.1016/j.ejpb.2020.05.00410.1016/j.ejpb.2020.05.004 ↗
37. 10.1021/acs.molpharmaceut.5b0014610.1021/acs.molpharmaceut.5b00146 ↗
38. 10.1515/ntrev-2022-002110.1515/ntrev-2022-0021 ↗
39. 10.1021/jp510103m10.1021/jp510103m ↗
40. 10.1007/s11356-020-10563-z10.1007/s11356-020-10563-z ↗
41. 10.1007/s00204-021-03191-010.1007/s00204-021-03191-0 ↗
42. 10.1016/B0-12-370879-6/00079-X10.1016/B0-12-370879-6/00079-X ↗
43. 10.1007/s13346-020-00891-510.1007/s13346-020-00891-5 ↗
44. 10.1016/j.jdsr.2009.03.00410.1016/j.jdsr.2009.03.004 ↗
45. 10.1016/j.toxlet.2007.10.00410.1016/j.toxlet.2007.10.004 ↗
46. 10.1186/1743-8977-7-2010.1186/1743-8977-7-20 ↗
47. 10.1186/1743-8977-8-1810.1186/1743-8977-8-18 ↗
48. 10.1161/01.RES.0000255691.76142.4a10.1161/01.RES.0000255691.76142.4a ↗
49. 10.1038/gt.2008.6010.1038/gt.2008.60 ↗
50. Holland N. · J. Nanomed. Nanotechnol. · 2015 · 6 · 1
51. 10.1016/j.taap.2019.01.00610.1016/j.taap.2019.01.006 ↗
52. 10.1016/j.toxlet.2009.01.02010.1016/j.toxlet.2009.01.020 ↗
53. 10.1016/j.toxlet.2012.01.00110.1016/j.toxlet.2012.01.001 ↗
54. 10.1080/0191312070169622110.1080/01913120701696221 ↗
55. 10.1074/jbc.M113.53132710.1074/jbc.M113.531327 ↗
56. 10.1021/nn303449n10.1021/nn303449n ↗
57. 10.1080/0895837070187466310.1080/08958370701874663 ↗
58. 10.1021/acsnano.1c0723710.1021/acsnano.1c07237 ↗
59. 10.1016/j.lfs.2018.09.00110.1016/j.lfs.2018.09.001 ↗
60. Lansdown A. B. G. · Adv. Pharmacol. Sci. · 2010 · 2010 · 910686
61. 10.1016/S1054-3589(08)61036-410.1016/S1054-3589(08)61036-4 ↗
62. 10.1186/s12989-014-0049-110.1186/s12989-014-0049-1 ↗
63. 10.1016/j.toxlet.2015.07.00110.1016/j.toxlet.2015.07.001 ↗
64. 10.1080/0895837049043959710.1080/08958370490439597 ↗